Document is current

Article History

Received: 15 October 2017

Accepted: 15 January 2018

First Online: 30 January 2018

Ethics approval and consent to participate

: The study was reviewed and approved by an Independent Ethics Committee in Kazakhstan (Central Commission for Ethics at the Ministry of Health of the Republic of Kazakhstan) and by Local Ethics Committees in Kazakhstan, Azerbaijan and Ukraine (Ethics Committee at Semey State Medical University, Almaty, Kazakhstan; Ethics Committee at Scientific Research Institute of Lung Diseases in Baku, Azerbaijan; Commission for Ethics at National Institute of Phthisiology and Pulmonology F.G. Yanovsky of NAMS, Kiev, Ukraine; Commission for Ethics at Center for Primary Health Care #2 of Shevchenko District, Kiev, Ukraine), according to the local legal requirements. Written informed consent was obtained from each participant before any procedures or data collection related to the study.

: Not applicable.

: The study was sponsored by GlaxoSmithKline (GSK) marketing a number of treatments for COPD, Allergic Rhinitis, and Asthma.DN, YF, LI, OG, EM, IA, NN report grants from GSK, during the conduct of the study; personal fees from GSK, outside the submitted work.KM and JM are employees of GSK. AV and LT are GSK employees and shareholders.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.